Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration

Stem Cells

Volumn 17, Issue 6, 1999, Pages 316-326

  De Serres, Mark ^a   Yeager, Russ L ^a   Dillberger, John E ^a   Lalonde, Guy ^b   Gardner, Guy H ^a   Rubens, Cathleen A ^a   Simkins, Anita H ^a   Sailstad, Jeffry M ^a   Mcnulty, Michael J ^a   Woolley, Joseph L ^a  

^a GLAXOSMITHKLINE   (United States)

^b AFFYMAX RESEARCH INSTITUTE   (United States)

Author keywords

GW395058; Hematology; Mimetic peptide; Monkey; PEGylated; Pharmacokinetics; Rat; Thrombopoietin

Indexed keywords

AF 13948; GW 395058; RECOMBINANT PROTEIN; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT; RHESUS MONKEY; SPECIES DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 0032757204     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.170316     Document Type: Article

References (20)

1. Kudoh S, Yamada M. Cytokine in cancer chemotherapy - clinical trials of IL-3, IL-11 and thrombopoietin against thrombocytopenia. Gan to Kagaku Ryoho J 1998;25:171-176.
2. Tepler I, Elias L, Smith JW, 2nd et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-3614.
3. Isaacs C, Robert NJ, Bailey FA et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15:3368-3377.
4. Kaushansky K. Thrombopoietin: the primary regulator of platelet production [see comments]. Blood 1995;86:419-431.
5. Kato T, Ogami K, Shimada Y et al. Purification and characterization of thrombopoietin [published erratum appears in J Biochem (Tokyo) 1996;119:208]. J Biochem 1995;118:229-236.
6. Harker LA, Hunt P, Marzec UM et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996;87:1833-1844.
7. Kabaya K, Akahori H, Shibuya K et al. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. STEM CELLS 1996;14:651-660.
8. Akahori H, Shibuya K, Obuchi M et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996;94:722-728.
9. Akahori H, Shibuya K, Ozai M et al. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. STEM CELLS 1996;14:678-689.
10. Shibuya K, Akahori H, Takahashi K et al. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 1998;91:37-45.
11. Andrews RG, Winkler A, Myerson D et al. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. STEM CELLS 1996;14:661-677.
12. Molineux G, Hartley CA, McElroy P et al. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996;88:1509-1514.
13. Harker LA, Marzec UM, Hunt P et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996;88:511-521.
14. Harker LA, Marzec UM, Kelly AB et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakayocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997;89:155-165.
15. PJB Publications Ltd. Amgen halts growth factor trials. Scrip 1998;2370:20.
16. Cwirla SE, Balasubramanian P, Duffin DJ et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997;276:1696-1699.
17. Singer SC, Tansik RL, Dev IK et al. Pegylated thrombopoietin (TPO)-mimetic peptides bind human TPO receptor causing proliferation and maturation of megakaryocytes. Blood 1998;92:568a.
18. Boytos CM, Rudolph SK, Merrell C et al. Pegylated thrombopoietin-mimetic peptides elevate blood platelets and ablate the chemotherapy-induced platelet nadir in mice. Blood 1998;92:377a.
19. de Serres M, Ellis B, Dillberger JE et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. STEM CELLS 1999;14:203-209.
20. Kuter DJ. Thrombopoietin: biology, clinical applications, role in the donor setting. J Clin Apheresis 1996;11:149-159.